Gökçe Güven Açık

Gökçe Güven Açık

Auto-generated profile, based on publicly available information

Gökçe Güven Açık

Ankara Halk Sağlığı Moleküler Tanı Laboratuvarı

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2023 in Journal of Contemporary Medicine
Verified
Journal Article
Open access
PDF file
BGBurcu Gürer Giray
Burcu Gürer Giray
GAGökçe Güven Açik
Gökçe Güven Açik
Objective: Our study focused on retrospectively assessing variant of concern, specified by the World Health Organization (WHO), with one-step reverse transcription and real-time polymerase chain reaction (RT-PCR) test in SARS-CoV-2 positive patients after three doses of attenuated COVID-19 vaccine. Methods: 8.520 samples transported with viral nucleic acid buffer (vNAT) tubes between June 2021 and January 31, 2022, were tested and included in the study. All the patients whose samples were included in our research had 3 doses of CoronaVac (Sinovac Life Science Co, Ltd, Beijing, China). Gender distribution was 4686 (55%) female and 3834 ( 45%) males. Variant specific genome regions only found in B.1.351, P.1 and B.1.1.7 as well as ORF1ab and N gene regions are investigated by the Bio-Speedy® Emerging Plus kit (Bioeksen AR-GE Technologies, Turkey) used to identify the variants in the study. Results: All 8.520 samples were SARS-CoV-2 RT-PCR positive. Our study detected alpha and delta variants in 1460 (17.14%) and 3570 (41.9%) patients respectively. 2570 (30.16%) patients did not have any variants according to test results. It was observed that the spread of beta, gamma and other suspicious variants remained at relatively low rates. Conclusion: The delta variant became dominant from July until to the end of the year. Declining delta variant rates and increasing cases of suspected variants towards the beginning of December 2021 suggest the omicron variant. Therefore, molecular surveillance studies that are planned to take epidemiological data into consideration and to examine the prevalence and gene-based analysis of local and worldwide variants are required.

3 November 2022 in The European Research Journal
Verified
Journal Article
Open access
PDF file
BGBurcu Gürer Giray
Burcu Gürer Giray
GAGökçe Güven Açık
Gökçe Güven Açık
SBSevda Meryem Baş
Sevda Meryem Baş
YBYUNUS EMRE BULUT
YUNUS EMRE BULUT
MKMustafa Sırrı Kotanoğlu
Mustafa Sırrı Kotanoğlu
Objectives: Main purpose of this study was evaluating inactive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine subsequent anti-S1 IgG feedback and the aspects involved in such reactions for professionals in healthcare (HCP) as the dominant risk group.Methods: Thirty-six HCPs with previous COVID-19 infection and 164 with no priors, 200 in total, who was working in the Ankara Public Health Molecular Diagnosis Laboratory were included. Main tool of identifying humoral immune response quantifably in serum samples which were obtained 28 days after administering each of two doses of vaccine was Roche Elecsys SARS-CoV-2 kit.Results: Average antibody levels of 164 negative HCPs were 15.82 ± 8.59 IU/mL and 26.042 ± 10.73 IU/mL while 36 positive HCPs demonstrated antibody responses as 66.083 ± 33.927 IU/mL and 90 ± 27.012 IU/mL 28 days after each of two doses of vaccine for both individual groups respectively. A statistically meaningful difference was found in antibody levels after two vaccine doses in both groups (p < 0.0001). The authors observed statistically higher average antibody levels after initial vaccine dosage in HCPs with infection than the antibody levels of naive individuals after second dose (p < 0.0001). Age, gender and vaccination feedback did not have a statistically meaningful disparity (p > 0.05).Conclusions: It was concluded that the average antibody level achieved after inital dose n HCPs with COVID-19 infection was surpassing the average antibody level obtained after the second dose in naive HCPs. The authors recommend further clinical researches on antibody levels and the extent of protection to prohibit COVID-19

3 March 2023 in The European Research Journal
Verified
Journal Article
Open access
PDF file
BGBurcu Gürer Giray
Burcu Gürer Giray
GAGökçe Güven Açık
Gökçe Güven Açık
Objectives: Reverse transcription and real-time polymerase chain reaction (RT-qPCR) based on the SARS-CoV-2 viral RNA demonstration is the gold standard in diagnosis. Data files obtained from PCR devices should be analysed by a specialist physician and results should be transferred to Laboratory Information Management System (LIMS). CAtenA Smart PCR (Ventura, Ankara, Türkiye) program is a local bioinformatics software that assess PCR data files with artificial intelligence, submits to expert approval and transfers the approved results to LIMS. The aim of this study is to investigate its accuracy and matching success rate with expert analysis. Methods: A total of 9400 RT-qPCR test results studied in Ankara Provincial Health Directorate Public Health Molecular Diagnosis Laboratory were compared with respect to expert evaluation and CAtenA results. Results: It was determined that the preliminary evaluation results of the CAtenA matched 86% of the negative and 90% of the positive results provided by expert analysis. 987 tests which CAtenA determined as inconclusive and suggested repeating PCR were found either negative or positive by expert analysis. A significant difference between positive and negative matching success rates and artificial intelligence (AI) based software overall accuracy was found and associated with the missed tests of the AI. Conclusions: As a result, it was suggested there is a low risk of confirming false positive results without expert analysis and test repetitions would cause losing time along with extra test costs. It was agreed that the PCR analysis used in CAtenA should be improved particularly in terms of test repetitions.

30 April 2023 in Journal of International Health Sciences and Management
Verified
Journal Article
Open access
PDF file
BGBurcu Gürer Giray
Burcu Gürer Giray
GAGökçe Güven Açik
Gökçe Güven Açik
YBYUNUS EMRE BULUT
YUNUS EMRE BULUT
AŞAsiye Çiğdem Şi̇mŞek
Asiye Çiğdem Şi̇mŞek
MKMustafa Sırrı Kotanoğlu
Mustafa Sırrı Kotanoğlu
Aim: Importance of laboratory diagnosis has come to the spotlight once again with the Covid-19 pandemic caused by Sars-CoV-2 and significant changes have taken place in terms of laboratory operation. A global effort has emerged when all healthcare professionals faced a biological threat. Interlaboratory collaboration and multidisciplinary approach contributed to this effort. This study aims to explain step-by-step establishment of a fully capable laboratory for Sars-CoV-2 diagnosis to support local and global fight for the COVID-19 pandemic. Methods: Several precautions were taken, and disaster plans were updated because of the changes in employee health and workload distribution. Some of these are setting up a laboratory from scratch for microorganism diagnostic tests performed in pandemic cases, measures for healthcare workers, personnel assignment planning, changes in the variety and number of tests, innovations in quality standards and the contribution of laboratories to scientific studies. Results: XXXXX Molecular Diagnostic Laboratory has become one of the laboratories in Türkiye where Sars-Cov-2 and its mutations have been studied the most with 1,710,856 samples between 01 October 2020 and 01 May 2022 since its establishment and it has become the laboratory with the highest number of equipment and technical personnel in the capital. Conclusion: This study summarizes all the phases of XXXXX Molecular Diagnostic Laboratory beginning with its establishment from the scratch and covers all the steps to render this facility fully operational. Keywords: COVID-19, laboratory disaster planning, laboratory staff, personal protective equipment, Sars-CoV-2

15 October 2023 in Black Sea Journal of Health Science
Verified
Journal Article
Closed access
BGBurcu Gürer Giray
Burcu Gürer Giray
GAGökçe Güven Açık
Gökçe Güven Açık
EGEfdal OKTAY GULTEKIN
Efdal OKTAY GULTEKIN
Günümüzde COVID-19'un kesin tanısı için en önemli yöntem, nazofaringeal sürüntü (NS) örneklerinde şiddetli akut solunum sendromu koronavirüs 2 (SARS-CoV-2) RNA'sının RT-PCR ile tanımlanmasıdır. Nazofaringeal sürüntü örneğinin alınması bazen olumsuz etkileri olan rahatsız edici bir işlem olup, örneklemeyi yapan sağlık personeli için de enfeksiyon riski oluşturmaktadır. SARS-CoV-2 tanısında tükürük örneğini kullanmak NS'ye göre daha az invaziv alternatif bir yöntemdir. Altın standart NS ile tükürük protokollerinin uyumunu değerlendiren çalışmalar sınırlıdır. Bu çalışmanın amacı, PCR bazlı SARS-CoV-2 tanısında, sağlık çalışanı tarafından alınan NS örneği ile tükürük örneği ve kişinin kendinden NS alma yöntemini karşılaştırmaktır. 2178 hastadan alınan tükürük ve NS örnekleme çeşitleri SARS-CoV-2 varlığı açısından RT-PCR ile analiz edilmiştir. Örneklerinden en az birinde SARS-CoV-2 tespit edilen 684 hastanın, sağlık çalışanı tarafından alınan NS örneğinin 606'sı (%88,59), kişinin kendinden aldığı NS örneğinin 402'si (%58,77) ve tükürük örneğinin 456'sı (%66,66) pozitif bulunmuştur. Kişinin kendinden aldığı NS örneği ve tükürük örneklerinin kullanılabilmesi istatistik olarak anlamlı bulunmuştur. NS örneklerine alternatif yöntemin olması hastaları invaziv ve ağrılı bir işlemden kurtaracak ve örnek alan sağlık personelinin enfeksiyon riskini azaltacaktır. SARS-CoV-2 tanısında tükürük örneklerinin ya da kişinin kendinden aldığı NS örneğinin test için kullanımı, hastanelerin iş yükünü azaltabilir, test sonuçlarının süresini kısaltabilir, asemptomatik popülasyonları test etmek için daha fazla kapasite sağlayarak enfekte hastaların hızlı bir şekilde izolasyonunu sağlayabilecektir.

3 September 2023 in The European Research Journal
Verified
Journal Article
Open access
PDF file
BGBurcu Gürer Giray
Burcu Gürer Giray
GAGökçe Güven Açık
Gökçe Güven Açık
Objectives: Quantitative reverse transcription‐polymerase chain reaction (qPCR) is used as the gold standard method to diagnose COVID-19 infection caused by SARS-CoV-2 which is the cause of the most important epidemic in world history. It was aimed to compare the results of two of the most commonly used commercial kits for the diagnosis of SARS-CoV-2 mutation in our laboratory during the pandemic. Methods: Our study included 5000 SARS-CoV-2 PCR positive nasopharyngeal swab samples (2500 L452R mutation positive samples, 2500 L452R mutation negative samples). PCR positivity and negativity of the L452R mutation of the positive SARS-CoV-2 positive samples were identified with the Diagnovital® (DIAGNO5plex NS SARS-CoV-2 Real Time PCR Kit [A1 Life Sciences Istanbul]) kit. The mentioned samples were also studied with a different commercial PCR kit, Bio-Speedy® (SARS-CoV-2 Emerging Plus Real Time PCR Kit [Bioeksen R&D Technologies Istanbul]). Results: A total of 5000 samples included in the study were concluded as SARS-CoV-2 positive with both tests. One hundred and fifty of 2500 samples that were found positive for SARS-CoV-2 but negative for L452R mutations with the Diagnovital® kit were found positive with the Bio-Speedy® kit for SARS-CoV-2. The compatability between the two kits was found to be high (Kappa= 0.940). The mean Ct values of the samples found positive with the Diagnovital® kit and Bio-Speedy® kit were 24.15 ± 6.75 and 20.72 ± 7.17, respectively and the difference was statistically significant. Conclusions: It was determined the two commercial kits included in the study were extremely compatible based on their analysis. Therefore both kits can be used safely for COVID-19 symptomatic patients.